GLP-1 medicines exert broad efficacy beyond weight loss by recruiting neural and immune circuits

While Type 2 diabetes and obesity are often managed with GLP-1 receptor agonists, their broader therapeutic benefits across cardiovascular, renal, and hepatic systems are increasingly recognized but not fully understood. This review explores the diverse, weight-loss-independent mechanisms by which GLP-1R agonism improves organismal health, highlighting the need to define dose-response relationships for these specific actions. Understanding these mechanisms is crucial for optimizing the full therapeutic potential of GLP-1 medicines.

This paper is a review/perspective, synthesizing existing literature on the diverse mechanisms of GLP-1 medicines beyond their primary weight-loss effects. It analyzes how GLP-1R agonism influences neural and immune circuits, inter-organ communication, and local receptor engagement. The authors did not conduct new experiments but rather interpreted a broad body of preclinical and clinical evidence to identify areas for future research, particularly regarding dose-response relationships for non-weight-loss benefits.

GLP-1 receptor agonism extends its therapeutic reach far beyond weight loss, demonstrating broad efficacy across multiple organ systems. The review highlights that GLP-1R agonism actively recruits neural and immune circuits, fostering beneficial inter-organ communication. Local GLP-1Rs are engaged to improve cardiovascular, renal, hepatic, and musculoskeletal health.

These actions collectively contribute to enhanced organismal health, independent of changes in body weight. The authors emphasize that understanding the specific dose-response relationships for these non-weight-loss mechanisms is crucial for optimizing the full therapeutic potential of GLP-1 medicines.